HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00752427

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Medication studyAges 65+
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 65 years.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateJune 2004
Recruitment status
Completed
Enrollment listed in the registry
86
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
Over 65 Years
Official registry ID
NCT00752427
Official title
Show the full official title

R076477-SCH-702: a 24 Week Open-Label Extension to R076477-SCH-302

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone ER OROS®.

Who was this study for?

Listed age limits: from 65 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me